Analysed Genmab A/S (GNMSF:OTCMKTS) News Sources
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Taiwan News
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early ...
Le Lézard
Here are Monday's biggest analyst calls: Nvidia, Apple, Netflix, Amazon, CrowdStrike, Blue Owl, Twilio & more
CNBC
Here Are Monday’s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More
24/7 Wall St.
Greaves Electric Mobility details allocation of fresh-issue proceeds as Ampere enters top five
ET Auto
What is the current price of Genmab A/S (GNMSF:OTCMKTS)?
The current price of Genmab A/S (GNMSF:OTCMKTS) is $290.0.
Genmab A/S (GNMSF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of Genmab A/S (GNMSF:OTCMKTS) since the previous trading day is $0.00.
Genmab A/S (GNMSF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of Genmab A/S (GNMSF:OTCMKTS) since the previous trading day is 0.00%.
What is This Week's average sentiment score for Genmab A/S (GNMSF:OTCMKTS)?
This Week's average sentiment score for Genmab A/S (GNMSF:OTCMKTS) is 69 out of 100.
What is This Week's average sentiment for Genmab A/S (GNMSF:OTCMKTS)?
This Week's sentiment for Genmab A/S (GNMSF:OTCMKTS) is .
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.